IN.IS.E.C.B.EX-F.1-5 E.DL/ DE000A0Z3SZ8
5FPD2023-02-03 5:45:55 PM | Chg. -0.99 | Open | High | Low | Previous Close |
---|---|---|---|---|---|
110.98XXP | -0.89% | 111.89 | 112.16 | 110.71 | 111.97 |
GlobeNewswire
04-24
Perceptyx Launches Activate, HR’s Missing Link Between Employee Insight and Impact
GlobeNewswire
03-05
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual ...
GlobeNewswire
02-28
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full...
GlobeNewswire
01-03
Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
2023-11-09
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
GlobeNewswire
2023-11-07
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
GlobeNewswire
2023-10-31
Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and In...
GlobeNewswire
2023-09-27
Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Im...
GlobeNewswire
2023-09-11
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Ce...